Kleo Pharmaceuticals has entered into a drug development agreement with PeptiDream, an emerging public pharmaceutical company traded on the Tokyo exchange.

Kleo Pharmaceuticals Inc. is a biotechnology company initially formed on the basis of intellectual property from the Spiegel Lab at Yale University and funded by a series A round led by New Haven based Biohaven Pharmaceuticals.

The company was founded by Dr. David Spiegel and Roy Prieb and is focused on developing a new class of targeted immunotherapies.